Back to Journals » Clinical Interventions in Aging » Volume 1 » Issue 4

Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy

Authors Glen M Blake, Ignac Fogelman

Published 15 January 2007 Volume 2006:1(4) Pages 367—375

Glen M Blake, Ignac Fogelman

King’s College London School of Medicine, London, UK

Abstract: Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and hip fractures. Evidence for the safety and efficacy of strontium ranelate comes from two large multinational trials, the SOTI (Spinal Osteoporosis Therapeutic Intervention) and TROPOS (Treatment Of Postmenopausal Osteoporosis) studies. The SOTI study evaluated vertebral fracture prevention in 1649 postmenopausal women with a mean age of 69 y. The subjects all had at least one previous vertebral fracture and a low spine bone mineral density (BMD) (equivalent to a Hologic spine T-score below –1.9). The strontium ranelate group had a 41% lower risk of a new vertebral fracture than the placebo group over the three-year study period (relative risk [RR]=0.59; 95% confidence interval [CI]: 0.48–0.73; p<0.001). The TROPOS study evaluated non-vertebral fracture prevention in 5091 postmenopausal women with a mean age of 77 y. The subjects were aged 74 y and over (or 70–74 y with one additional risk factor) and a low femoral neck BMD (equivalent to an NHANES III [Third National Health and Nutrition Examination Survey] T-score below –2.2). Over the three-year study period there was a 16% reduction in all non-vertebral fractures (RR=0.84; 95% CI 0.702–0.995; p=0.04) and a 19% reduction at the principal sites for non-vertebral fractures. The TROPOS study was not powered to investigate hip fracture risk. However, in a high risk group of women aged 74 y and over and with an NHANES III femoral neck T-score less than –2.4 there was a 36% reduction in hip fracture risk (RR=0.64; 95% CI: 0.412–0.997; p=0.046). The overall incidence of adverse events did not differ significantly from placebo and were generally mild and transient, the most common being nausea and diarrhea. Strontium ranelate is a useful addition to the range of anti-fracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and hip fractures in women aged 80 y and over.

Keywords: Strontium ranelate, osteoporosis treatment, postmenopausal women, vertebral fracture prevention, hip fracture prevention

Download Article [PDF] 

Readers of this article also read:

Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy

Amreddy N, Muralidharan R, Babu A, Mehta M, Johnson EV, Zhao YD, Munshi A, Ramesh R

International Journal of Nanomedicine 2015, 10:6773-6788

Published Date: 29 October 2015

Effect of surface roughness on osteogenesis in vitro and osseointegration in vivo of carbon fiber-reinforced polyetheretherketone–nanohydroxyapatite composite

Deng Y, Liu X, Xu A, Wang L, Luo Z, Zheng Y, Deng F, Wei J, Tang Z, Wei S

International Journal of Nanomedicine 2015, 10:1425-1447

Published Date: 17 February 2015

NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency

Burgess BL, He Y, Baker MM, Luo B, Carroll SF, Forte TM, Oda MN

International Journal of Nanomedicine 2013, 8:4733-4743

Published Date: 12 December 2013

Clinical utility of asthma biomarkers: from bench to bedside

Vijverberg SJH, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L

Biologics: Targets and Therapy 2013, 7:199-210

Published Date: 29 August 2013

Priorities for people living with dementia: education, counseling, research

Kerstin Stieber Roger

Clinical Interventions in Aging 2008, 3:573-579

Published Date: 12 September 2008

Extracorporeal shock waves as curative therapy for varicose veins?

Fiorenzo Angehrn, Christoph Kuhn, Ortrud Sonnabend, Axel Voss

Clinical Interventions in Aging 2008, 3:175-182

Published Date: 7 March 2008

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates

Jean-Yves Reginster, Véronique Rabenda

Clinical Interventions in Aging 2006, 1:415-423

Published Date: 15 January 2007

Dietary essential fatty acids and gender-specific behavioral responses in cranially irradiated rats

T David Elkin, Michael O Wollan, Stacy L Anderson, Robert Gaston, William Meyer, Bernard F Fuemmeler, Frank A Holloway, Rex E Martin

Neuropsychiatric Disease and Treatment 2006, 2:365-374

Published Date: 15 September 2006